IP Library › Granted Patent US 11,618,892
Granted Patent B2
US 11,618,892 · App. 16/599,407 · Granted Apr 4, 2023

Mutant reverse transcriptase with increased thermal stability as well as products, methods and uses involving the same

Inventors: Christian Helmut Bell (Basel, CH); Harald Sobek (Biberach, DE); Heiko Walch (Munich, DE); Kiyoshi Yasukawa (Kyoto, JP); Misato Baba (Hyto, JP)
Assignee: Roche Diagnostics Operations, Inc.
C12N9/1276C12P19/34C12Q1/68C12Y207/07049
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,618,892
App. No.
16/599,407
Granted
Apr 4, 2023
Kind
B2
Abstract

The present invention relates to a mutant reverse transcriptase (RT) with increased thermal stability relative to the wildtype, a nucleic acid encoding the mutant RT, a cell comprising the mutant RT or the nucleic acid, a kit comprising the mutant RT, the use of the mutant RT for cDNA synthesis, method for reverse transcription of RNA comprising synthesizing cDNA with the use of the mutant RT and a method for detecting an RNA marker in a sample with the use of the mutant RT.

Claims (14)

1. A mutant reverse transcriptase (RT) with an increased thermal stability relative to a wildtype RT consisting of SEQ ID NO:1, the mutant RT consisting of

an amino acid sequence that has only six amino acid substitutions of SEQ ID NO:1, wherein

Ala at position 32 is substituted with Val (A32V);

Leu at position 72 is substituted with Arg (L72R);

Glu at position 286 is substituted with Arg (E286R);

Glu at position 302 is substituted with Lys (E302K);

Trp at position 388 is substituted with Arg (W388R); and

Leu at position 435 is substituted with Arg (L435R),

wherein the mutant RT exhibits a reverse transcriptase activity, and wherein the mutant RT also has an increased thermal stability relative to a mutant MM3, wherein the mutant MM3 has an amino acid sequence that differs from the amino acid sequence of SEQ ID NO:1 and only has three amino acid substitutions of SEQ ID NO:1, wherein Glu at position 286 is substituted with Arg (E286R), Glu at position 302 is substituted with Lys (E302K) and Leu at position 435 is substituted with Arg (L435R).

2. The mutant RT of claim 1 , wherein the increased thermal stability is determined by measuring the reverse transcriptase activity of the mutant RT after a thermal treatment.

3. The mutant RT of claim 1 , wherein the reverse transcriptase activity of the mutant RT is at least 50% of the reverse transcriptase activity of the wildtype RT.

4. The mutant RT of claim 1 consisting of an amino acid sequence of SEQ ID NO:2.

5. A cell comprising the mutant RT of claim 1 .

6. A kit for performing a reverse transcription reaction, comprising the mutant RT of claim 1 .

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 11, 2019
From: BABA, MISATO; YASUKAWA, KYOSHI
To: KYOTO UNIVERSITY
Reel/Frame 050687/0875 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 11, 2019
From: KYOTO UNIVERSITY
To: ROCHE DIAGNOSTICS GMBH
Reel/Frame 050687/0958 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 11, 2019
From: ROCHE DIAGNOSTICS GMBH
To: ROCHE DIAGNOSTICS OPERATIONS, INC.
Reel/Frame 050688/0019 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 11, 2019
From: BELL, CHRISTIAN HELMUT; SOBEK, HARALD; WALCH, HEIKO
To: ROCHE DIAGNOSTICS GMBH
Reel/Frame 050688/0107 →
Priority Claims (1)
EP 17000621 · Apr 11, 2017 · regional
Continuity (2)
Continuation PCTEP2018059170 · Apr 10, 2018
Related Publication 20200040316A1 · Feb 6, 2020